 Home > Active Ingredient News > Drugs Articles > Express is better than the first-line standard therapy for the first time in 20 years, and the innovative ADC combination reaches the phase 3 clinical endpoint

Express is better than the first-line standard therapy for the first time in 20 years, and the innovative ADC combination reaches the phase 3 clinical endpoint

 Last Update: 2021-08-29
 Source: Internet
 Author: User

Tags

nk cells cancer

concerta drug class

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

On August 9, 2021, Roche announced that its "first-in-class" CD79b-targeting antibody-conjugated drug (ADC) Polivy (polatuzumab vedotin) combined with chemotherapy regimen R-CHP will be diffuse in the first-line treatment.

The “first-in-class” CD79b-targeted antibody-conjugated drug (ADC) Polivy (polatuzumab vedotin) Polivy+R-CHP is the first treatment plan to significantly improve the outcome of such patients in 20 years compared with standard treatment

DLBCL is the most common type of non-Hodgkin's lymphoma (NHL), accounting for about one-third of NHL

The CD79b protein is specifically expressed in most B cells, making it a promising target for the development of new therapies

Polivy specifically binds to CD79b on tumor cells to deliver anti-cancer drugs to kill these B cells and minimize damage to normal cells

The POLARIX clinical trial evaluates Polivy+Rituximab+Cyclophosphamide+Doxorubicin+Prednisone (R-CHP) chemotherapy in previously untreated DLBCL patients, compared with Rituximab+Cyclophosphate Efficacy, safety and pharmacokinetics of amide + doxorubicin + vincristine + prednisone (R-CHOP) standard treatment

"Since 40% of DLBCL patients relapse after initial treatment, achieving meaningful therapeutic effects in a first-line treatment environment may be transformative

Reference materials:

[1] Ad hoc announcement pursuant to Art.

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

Related Products

Tirzepatide Lyophilized powder Vial 5mg 10mg 15mg 20mg 30mg customize 99% Purity with third side checking report

CAS No.: 2023788-19-2

Pharmacy Grade

$50-60/UNIT FOB

Wight loss Lyophilized Semaglutide Petide powder CAS 910463-68-2 with 99.9% purity

CAS No.: 910463-68-2

Pharmacy Grade

$140-175/G FOB

High Quality (E,E,E,E)-Squalene CAS NO 111-02-4 GMP ISO9001 EP Pharma grade Manufacture

CAS No.: 111-02-4

EP Pharma grade

$400-405/KG FOB

Hot Tags

united states jobs(223)

jobs united states(236)

1 year treasury(277)

1 year subscription(296)

single use technology(195)

announcements today(81)

80 20 company(94)

united states logo(227)

ups united states(221)

healthy food name(42)

Hot Articles

The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.